With a positivity rate of more than 10% in 45 districts, the pandemic has become a source of concern in the Northeast states.
In the last 24 hours, which ended at 8 a.m. on Thursday, India reported 45,892 new coronavirus cases and 817 deaths. As a result, the country’s total caseload has risen to 3,07,09,557, while the death toll has risen to 4,05,028. The number of active cases in the country has fallen to 4,60,704 people.
According to news agency PTI, pharmaceutical companies Sanofi and GSK have received approval for a Phase 3 clinical study in India to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein Covid-19 vaccine candidate.
According to Sanofi, the global, randomised, double-blind Phase 3 trial will include more than 35,000 volunteers aged 18 and older from countries such as the United States, Asia, Africa, and Latin America.
As countries around the world rush to vaccinate their populations in response to more virulent variants, the global coronavirus death toll has surpassed the dreadful four million mark.